Gonorrhea Treatment Guidelines

Primary Treatment Recommendation

The Centers for Disease Control and Prevention recommends ceftriaxone 250 mg IM in a single dose PLUS azithromycin 1 g orally in a single dose for uncomplicated gonococcal infections of the cervix, urethra, rectum, and pharynx 1, 2
Azithromycin is preferred over doxycycline due to convenience and compliance advantages of single-dose therapy, and substantially higher prevalence of gonococcal resistance to tetracycline than to azithromycin 1

Alternative Regimens

If ceftriaxone is not available, the Centers for Disease Control and Prevention recommends cefixime 400 mg orally in a single dose PLUS azithromycin 1 g orally in a single dose, with a test-of-cure performed 1 week after treatment 3
For patients with severe cephalosporin allergy, azithromycin 2 g orally in a single dose is recommended, with a test-of-cure performed 1 week after treatment 3

Rationale for Dual Therapy

The Centers for Disease Control and Prevention recommends dual therapy due to rising antibiotic resistance patterns, which necessitate combination therapy to improve treatment efficacy and potentially delay emergence and spread of resistance to cephalosporins 1
Dual therapy also addresses possible chlamydial co-infection 2

Special Considerations

Pregnant women should not be treated with quinolones or tetracyclines, and the recommended treatment is a cephalosporin (ceftriaxone preferred), according to the Centers for Disease Control and Prevention 4
For treatment failure, culture relevant clinical specimens, perform antimicrobial susceptibility testing, and consult an infectious disease specialist, as recommended by the Centers for Disease Control and Prevention 2, 3

Partner Management

All sex partners from the preceding 60 days should be evaluated and treated, according to the Centers for Disease Control and Prevention 2, 3
Patients should avoid sexual intercourse until therapy is completed and both they and their partners are asymptomatic, as recommended by the Centers for Disease Control and Prevention 4

Important Clinical Considerations

Pharyngeal gonorrhea is more difficult to eradicate than urogenital or anorectal infections, according to the Centers for Disease Control and Prevention 4
Azithromycin 1 g alone is insufficient for gonorrhea treatment, as recommended by the Centers for Disease Control and Prevention 4

Gonorrhea Treatment Recommendations

Antimicrobial Resistance Considerations

Rising cefixime MICs have resulted in declining effectiveness for urogenital gonorrhea treatment, according to the Centers for Disease Control and Prevention 5
Dual therapy with two antimicrobials with different mechanisms of action is recommended to improve treatment efficacy and potentially delay emergence of cephalosporin resistance, as suggested by the Centers for Disease Control and Prevention 5
Quinolones (ciprofloxacin) are no longer recommended due to widespread resistance, as reported by the Centers for Disease Control and Prevention 6, 5

Site-Specific Considerations

Pharyngeal gonorrhea is more difficult to eradicate than urogenital or anorectal infections, according to the Centers for Disease Control and Prevention 6
Ceftriaxone has superior efficacy for pharyngeal infections compared to alternative treatments, as reported by the Centers for Disease Control and Prevention 5

Special Populations

Ceftriaxone is the only recommended treatment for Men who have Sex with Men (MSM) due to higher prevalence of resistant strains, as recommended by the Centers for Disease Control and Prevention 6, 5
Quinolones should not be used for infections in MSM, according to the Centers for Disease Control and Prevention 6
Ceftriaxone is the only recommended treatment for patients with history of recent foreign travel, as suggested by the Centers for Disease Control and Prevention 6

Partner Management

If partners' treatment cannot be ensured, expedited partner therapy may be considered, as recommended by the Centers for Disease Control and Prevention 6

Follow-Up Recommendations

Patients with persistent symptoms after treatment should be evaluated by culture for N. gonorrhoeae, and any isolates should be tested for antimicrobial susceptibility, as recommended by the Centers for Disease Control and Prevention 6
Consider retesting all patients 3 months after treatment due to high risk of reinfection, as suggested by the Centers for Disease Control and Prevention 6

Empiric Treatment for Gonorrhea and Chlamydia

Alternative Regimens

For patients with severe cephalosporin allergy, the Centers for Disease Control and Prevention recommends spectinomycin 2 g IM in a single dose, which has poor efficacy (only 52%) against pharyngeal gonorrhea 7
Patients with uncomplicated gonorrhea treated with recommended regimens do not need a test of cure, as stated by the Centers for Disease Control and Prevention 7

Important Clinical Considerations

Azithromycin 1 g alone is insufficient for gonorrhea treatment, with only 93% efficacy, according to the Centers for Disease Control and Prevention 8

Empiric Treatment for Chlamydia and Gonorrhea

Rationale for Dual Therapy

Co-infection is extremely common, with up to 40-50% of patients with gonorrhea also having chlamydia, making presumptive treatment for both organisms essential when empiric therapy is indicated, as recommended by the Centers for Disease Control and Prevention (CDC) 9, 10

Critical Pitfalls to Avoid

Never use quinolones for gonorrhea treatment due to widespread resistance, as advised by the CDC 9, 10
Ceftriaxone has superior efficacy for pharyngeal infections compared to oral alternatives, and is strongly preferred over cefixime for pharyngeal infections, as recommended by the CDC 9, 10

Gonorrhea Treatment Guidelines

Rationale for Current Regimen

The Centers for Disease Control and Prevention (CDC) recommends that patients with severe cephalosporin allergy use azithromycin 2 g orally once, with mandatory test-of-cure at 1 week, although this regimen has lower efficacy and higher gastrointestinal side effects 11
Pharyngeal gonorrhea is significantly more difficult to eradicate than urogenital or anorectal infections, and ceftriaxone 500 mg IM is the only reliably effective treatment for pharyngeal infections 11
Never use fluoroquinolones (ciprofloxacin, ofloxacin) for gonorrhea treatment due to widespread resistance, despite their historical effectiveness (99.8% cure rate in 1998) 11
Never use azithromycin 1 g alone due to insufficient efficacy (only 93% cure rate) 11
Patients treated with recommended regimens do not need routine test-of-cure unless symptoms persist, but mandatory test-of-cure at 1 week is required for patients receiving cefixime or azithromycin monotherapy 11
Patients with persistent symptoms should have culture with antimicrobial susceptibility testing 11

Treatment for Gonorrhoea

Site-Specific Considerations

Most cases of ceftriaxone treatment failure involve the pharynx, not urogenital sites, and both spectinomycin and gentamicin have poor efficacy in the pharynx, with one study showing only 2 of 10 individuals with pharyngeal gonorrhoea treated with gentamicin were cured 12

Treatment Failure Management

If treatment failure occurs, obtain specimens for culture and antimicrobial susceptibility testing immediately, and report the case to local public health officials within 24 hours, and consult an infectious disease specialist 12
For suspected ceftriaxone treatment failure, recommended regimens include gentamicin 240 mg intramuscularly PLUS azithromycin 2 g orally (single dose), spectinomycin 2 g intramuscularly PLUS azithromycin 2 g orally, and ertapenem 1 g intramuscularly for 3 days 12

Gonorrhea Treatment Guidelines

Primary Treatment Regimen

The Centers for Disease Control and Prevention (CDC) recommends cefixime 400 mg orally single dose PLUS azithromycin 1 g orally single dose as an alternative regimen when ceftriaxone is unavailable 13
Mandatory test-of-cure at 1 week is required with the cefixime and azithromycin regimen 13

Alternative Regimens

For patients with severe cephalosporin allergy, azithromycin 2 g orally single dose is an option, but has lower efficacy (only 93%) and high gastrointestinal side effects 13
Gentamicin 240 mg IM single dose PLUS azithromycin 2 g orally single dose is an alternative regimen with a 100% cure rate in clinical trials 14

Critical Site-Specific Considerations

Spectinomycin has only 52% efficacy for pharyngeal infections and should be avoided 13, 15
Gentamicin also has poor pharyngeal efficacy (only 20% cure rate in one study) 14

Partner Management

The CDC recommends evaluating and treating all sexual partners from the preceding 60 days 13
Partners should receive the same dual therapy regimen for both gonorrhea and chlamydia 13

Treatment Failure Management

If treatment failure is suspected, obtain specimens for culture and antimicrobial susceptibility testing immediately 14
Report the case to local public health officials within 24 hours 13, 14
Consult an infectious disease specialist 13, 14
Recommended salvage regimens include gentamicin 240 mg IM PLUS azithromycin 2 g orally or ertapenem 1 g IM for 3 days 14

Special Populations

In pregnancy, use ceftriaxone (preferred cephalosporin) PLUS azithromycin 1 g orally 15
Never use quinolones or tetracyclines in pregnancy 15
For men who have sex with men (MSM), do not use patient-delivered partner therapy due to high risk of undiagnosed coexisting STDs or HIV 13

Ceftriaxone 500mg IM + Azithromycin 1g: Treatment Assessment

Efficacy and Safety

Ceftriaxone achieves a 99.1% cure rate for uncomplicated urogenital and anorectal gonorrhea, as recommended by the CDC 16
Azithromycin 1g provides single-dose chlamydia coverage, eliminating the need for 7-day doxycycline in compliant patients, although the CDC recommends against using azithromycin 1g alone for gonorrhea due to its 93% efficacy 16
The use of quinolones (ciprofloxacin, ofloxacin) is no longer recommended due to widespread resistance, despite their historical 99.8% cure rates, as stated in the MMWR Recommendations and Reports 16

Treatment Guidelines

The CDC recommends ceftriaxone 500mg IM plus azithromycin 1g orally as the optimal single-dose dual therapy regimen for uncomplicated gonorrhea with presumptive chlamydia coverage 16
This regimen is effective in treating gonorrhea at cervical, urethral, rectal, and pharyngeal sites with a single administration, as supported by the MMWR Recommendations and Reports 16

Gonorrhea Treatment Guidelines

Mandatory Follow-Up Requirements

If nucleic acid amplification testing is positive at follow-up, confirm with culture, and all positive cultures should undergo phenotypic antimicrobial susceptibility testing, as recommended by the Centers for Disease Control and Prevention 17

Partner Management

Consider expedited partner therapy with oral combination therapy (cefixime 400 mg plus azithromycin 1 g) if partners cannot be linked to timely evaluation, according to the Centers for Disease Control and Prevention 17

Gonorrhea and Chlamydia Treatment Guidelines

Special Populations

The American College of Obstetricians and Gynecologists recommends using ceftriaxone 500 mg IM (single dose) + Azithromycin 1 g orally (single dose) in pregnant women, and advises against the use of doxycycline, quinolones, or tetracyclines in pregnancy 18

Men Who Have Sex with Men (MSM)

The Centers for Disease Control and Prevention recommends that men who have sex with men (MSM) should not be treated with quinolones due to higher prevalence of resistant strains 19
The Centers for Disease Control and Prevention also recommends that ceftriaxone is the only recommended treatment for MSM due to higher prevalence of resistant strains 20

Follow-Up Requirements

The Centers for Disease Control and Prevention recommends that if symptoms persist after treatment, culture with antimicrobial susceptibility testing should be obtained 19
The Centers for Disease Control and Prevention also recommends that if symptoms persist after treatment, culture with antimicrobial susceptibility testing should be obtained 20

Oral Treatment Options for Gonorrhea and Chlamydia

Special Populations

The American Academy of Ophthalmology recommends using cefixime 400 mg orally PLUS azithromycin 1 g orally in pregnant patients if injection is refused, as doxycycline is contraindicated in pregnancy 21
Doxycycline is contraindicated in pregnancy, nursing women, and children under 8 years, according to the American Academy of Ophthalmology 21

Gonorrhea Treatment Guidelines

Introduction to Gonorrhea Treatment

The Centers for Disease Control and Prevention recommends screening for syphilis with serology at the time of gonorrhea diagnosis, and co-testing for HIV should also be performed given the facilitation of HIV transmission by gonorrhea 22

Alternative Regimens

Oral cephalosporins are no longer first-line agents due to documented treatment failures in Europe, as reported by the Morbidity and Mortality Weekly Report 22

Critical Pitfalls to Avoid

The Morbidity and Mortality Weekly Report advises against using fluoroquinolones (ciprofloxacin, ofloxacin) for gonorrhea treatment due to widespread resistance 22

Gonorrhea Treatment Guidelines

Introduction to Gonorrhea Treatment

The Centers for Disease Control and Prevention recommends that patients with gonorrhea and their sexual partners from the preceding 60 days should be evaluated and treated for both gonorrhea and chlamydia, with the same dual therapy regimen 23

Partner Management

The American College of Obstetricians and Gynecologists and other guideline societies support the concept of expedited partner therapy, which may be considered when partners cannot be linked to timely evaluation, using oral combination therapy (cefixime 400 mg plus azithromycin 1 g), but this approach is not recommended for men who have sex with men (MSM) due to the high risk of undiagnosed coexisting STDs or HIV 23

Ceftriaxone Dosage for Gonorrhea

Pharmacokinetics and Efficacy

The 500 mg dose of ceftriaxone is particularly important for pharyngeal infections because extended-spectrum cephalosporins have marked variability in clearance and half-life within pharyngeal tissues, with nearly 90% being protein-bound in tonsillar tissue 24
For suspected ceftriaxone treatment failure, recommended salvage regimens include gentamicin 240 mg IM PLUS azithromycin 2 g orally (single dose), or ertapenem 1 g IM for 3 days 24
Higher doses of ceftriaxone (up to 3 g per dose with repeat dosing) are used in China without reported treatment failures, and a twice-daily dose of 2 g ceftriaxone would achieve sufficient free plasma concentrations for high-level resistant strains 24

Treatment of Uncomplicated Gonococcal Infection in Men

Primary Treatment Regimen

The Centers for Disease Control and Prevention recommends ceftriaxone 500 mg intramuscularly as a single dose, plus doxycycline 100 mg orally twice daily for 7 days, for the treatment of uncomplicated gonococcal infection in men, with a high cure rate 25

Critical Pitfalls to Avoid

The Centers for Disease Control and Prevention advises against using fluoroquinolones for gonorrhea treatment due to widespread resistance, despite their historical high cure rates 25
The Centers for Disease Control and Prevention recommends against using azithromycin 1 g alone for gonorrhea, as it has only 93% efficacy and risks rapid resistance emergence 25

Follow-Up Requirements

Patients treated with recommended ceftriaxone-based regimens do not need routine test-of-cure unless symptoms persist, according to the MMWR Recommendations and Reports 25
The MMWR Recommendations and Reports suggests considering retesting all patients at 3 months due to high reinfection risk 25

Treatment for Gonorrhea Exposure

Rationale for Presumptive Treatment

Gonorrhea transmission rates are high enough to warrant immediate treatment without waiting for test results, particularly because many infections are asymptomatic and patients may not return for follow-up, with co-infection with Chlamydia trachomatis occurring in 10-50% of gonorrhea cases, making dual therapy essential even for presumptive treatment 26, 27
The Centers for Disease Control and Prevention (CDC) recommends that all sexual partners from the preceding 60 days should be evaluated and treated for both gonorrhea and chlamydia, regardless of symptoms or test results, due to the high transmission rates and potential for serious sequelae 26, 27

Transmissibility Context

Gonorrhea is highly transmissible, with transmission occurring even from asymptomatic individuals, and many infections in women remain asymptomatic until complications like pelvic inflammatory disease develop, which can lead to tubal scarring, infertility, or ectopic pregnancy 26, 27

Gonorrhea Treatment Guidelines

Introduction to Gonorrhea Treatment

The Centers for Disease Control and Prevention (CDC) recommends dual therapy for gonorrhea treatment, which includes a combination of two antimicrobials, such as ceftriaxone and azithromycin, to address chlamydial coinfection and potentially delay cephalosporin resistance 28

Treatment Regimens

Cefixime should not be used as monotherapy without azithromycin or doxycycline, as this violates CDC dual therapy recommendations that mandate combination treatment to address chlamydial coinfection and potentially delay cephalosporin resistance 28
The CDC recommends ceftriaxone 500mg IM plus azithromycin 1g orally as the first-line treatment regimen for gonorrhea, and cefixime is only an alternative regimen when ceftriaxone is unavailable 28

Follow-Up Requirements

The CDC mandates test-of-cure at 1 week (7 days post-treatment) for all patients treated with cefixime-based regimens due to rising cefixime MICs and declining effectiveness 28
Test-of-cure should ideally use culture (allows antimicrobial susceptibility testing) or NAAT if culture is unavailable, and if NAAT is positive, confirm with culture and perform phenotypic antimicrobial susceptibility testing 28

Partner Management

The CDC recommends evaluating and treating all sexual partners from the preceding 60 days with the recommended dual therapy regimen: ceftriaxone 500mg IM plus azithromycin 1g orally 28
Partners should receive expedited partner therapy with cefixime 400mg plus azithromycin 1g if they cannot be linked to timely evaluation 28

Cefixime-Based Regimens for Uncomplicated Gonorrhea

Efficacy of Cefixime

The Centers for Disease Control and Prevention (CDC) recommends cefixime 400mg as an acceptable oral cephalosporin alternative when ceftriaxone is unavailable, with a 97.4% cure rate for uncomplicated urogenital and anorectal gonococcal infections 29

Preferred Treatment in Specific Situations

Ceftriaxone 500mg IM is the superior initial choice for patients with recent foreign travel, due to the increased risk of resistant strains 29
Ceftriaxone provides higher and more sustained bactericidal levels (98.9% cure rate) compared to cefixime (97.4% cure rate) 29

Management of Persistent Dysuria After Cefixime Treatment for Gonorrhea

Introduction to Gonorrhea Treatment

The Centers for Disease Control and Prevention (CDC) recommends immediate re-evaluation with culture and antimicrobial susceptibility testing, followed by re-treatment with ceftriaxone 250 mg IM plus azithromycin 1 g orally, as cefixime monotherapy has suboptimal efficacy 30

Critical Problems with Current Management

The CDC removed cefixime from first-line recommendations in 2012 due to documented treatment failures in Europe and rising resistance patterns, and it is only acceptable when ceftriaxone is unavailable 31

Immediate Next Steps

Collect specimens from all potentially infected sites for culture with antimicrobial susceptibility testing, as persistent symptoms after treatment suggest either treatment failure or reinfection 30, 32
Administer ceftriaxone 250 mg IM plus azithromycin 1 g orally as a single dose, preferably simultaneously and under direct observation, as this is the only CDC-recommended first-line regimen for gonorrhea treatment 30

Additional Considerations

Evaluate and treat all sexual partners from the preceding 60 days with the recommended dual therapy regimen (ceftriaxone 250 mg IM plus azithromycin 1 g orally), as most post-treatment infections result from reinfection rather than treatment failure 30, 33
Test for syphilis by serology and HIV at this visit, as gonorrhea facilitates HIV transmission and screening for syphilis should be performed when gonorrhea is detected 31, 33

Common Pitfalls to Avoid

Fluoroquinolones should not be used for gonorrhea treatment due to widespread resistance 31
Do not assume symptom resolution equals cure when suboptimal regimens were used—test-of-cure is mandatory 30

Evidence‑Based Recommendations for Gonorrhea Management (Cited)

Pharyngeal Infection Treatment Efficacy

Spectinomycin provides only about a 52 % cure rate for pharyngeal gonorrhea, making it insufficient as a sole therapy for this site. (CDC MMWR Recommendations and Reports, 2002) 34

Contraindicated Monotherapy Regimens

A single 1 g dose of azithromycin alone achieves roughly a 93 % cure rate for urogenital gonorrhea and is explicitly contraindicated because of its low efficacy and the rapid emergence of resistance. (CDC MMWR Recommendations and Reports, 2002) 34
Fluoroquinolones such as ciprofloxacin or ofloxacin should never be used for gonorrhea treatment due to widespread antimicrobial resistance, despite historical cure rates of 99.8 %. (CDC MMWR Recommendations and Reports, 2002) 35

Partner and Sexual Activity Guidance

Patients must refrain from sexual intercourse until the full treatment course is completed and both they and all treated partners are asymptomatic, to prevent ongoing transmission. (CDC MMWR Recommendations and Reports, 2002) 34

CDC Guidelines on Oral Regimens for Gonorrhea

Efficacy of Oral Cefixime

In adults with pharyngeal gonorrhea, a single oral dose of cefixime 200 mg achieves a cure rate of 78.9 % (95 % CI 54.5 %–94 %)—considerably lower than injectable regimens, indicating limited reliability of cefixime for pharyngeal infection. The Centers for Disease Control and Prevention (CDC) notes this limitation in its recommendations 36.

Contraindicated Therapies

The CDC advises against the use of fluoroquinolones (ciprofloxacin, ofloxacin) for gonorrhea treatment because of widespread antimicrobial resistance, even though these agents historically reported cure rates of ≈99.8 %. This shift reflects current resistance patterns that render fluoroquinolones ineffective. 37

Partner Management

The CDC recommends that all sexual partners from the preceding 60 days be evaluated and treated with the dual‑therapy regimen of cefexime 400 mg orally plus azithromycin 1 g orally when timely clinical evaluation is not possible, to ensure both gonorrhea and chlamydia are addressed. 37

CDC Recommendations on Co‑infection and Antibiotic Resistance in Gonorrhea and Chlamydia

Co‑infection Prevalence

In adult males with gonorrhea, co‑infection with Chlamydia trachomatis occurs in 20 %–50 % of cases, underscoring the need for simultaneous treatment of both pathogens. 38

Antibiotic Resistance Considerations

Fluoroquinolones (ciprofloxacin, ofloxacin) are contraindicated for gonorrhea because of widespread resistance, despite earlier reports of ≈ 99.8 % cure rates. The CDC advises against their use. 38

Presumptive Treatment Guidelines

Chlamydia treatment should not be omitted even when chlamydia testing is negative in a patient diagnosed with gonorrhea; presumptive dual therapy is recommended due to the high likelihood of co‑infection. This guidance comes from CDC recommendations. 38

Pregnancy Treatment Recommendations for Gonorrhea and Chlamydia Co‑Infection

Recommended Dual Therapy

For pregnant individuals with confirmed gonorrhea–chlamydia co‑infection, administer a single intramuscular dose of ceftriaxone 500 mg together with a single oral dose of azithromycin 1 g. 39

Medications to Avoid in Pregnancy

Doxycycline, quinolones, and all tetracyclines should not be used during pregnancy because of documented fetal safety concerns. 39

Acceptable Chlamydia Regimens in Pregnancy

The only recommended options for treating chlamydia in pregnant individuals are:
- Azithromycin 1 g given as a single oral dose, or
- Amoxicillin 500 mg taken three times daily for 7 days. 39